(Circulation. 1995;91:1929-1935.)
© 1995 American Heart Association, Inc.
Articles |
Rebound Increase in Thrombin Generation and Activity After Cessation of Intravenous Heparin in Patients With Acute Coronary Syndromes
From the Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC (C.B.G., J.M.M., M.W.K., C.G., E.B., R.A.H., E.M.O., R.M.C.); the Department of Pathology, University of Vermont Medical Center, Burlington, Vt (E.G.B., R.P.T.); and the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, Calif (A.G.).
Correspondence to Christopher B. Granger, MD, Box 3409, Duke University Medical Center, Durham, NC 27710.
Background The abrupt cessation of heparin and other thrombin inhibitors when used to treat acute coronary syndromes has been accompanied by a clustering of thrombotic events. It is unknown whether these events are the result of inadequate antithrombin therapy or whether they represent a rebound increase in thrombin activity. This study was designed to determine whether there is a true rebound, as defined by an increase followed by a subsequent decrease, in thrombin activity after discontinuation of intravenous heparin therapy.
Methods and Results Thirty-five patients with recent acute myocardial infarction or unstable angina who had received at least 48 hours of intravenous heparin were studied. Patients underwent ST-segment monitoring, and blood samples for determination of thrombin generation and activity were drawn at 0, 3, 6, 10, and 24 hours after heparin discontinuation. Median aPTT was 65 seconds before heparin discontinuation. Median fibrinopeptide A increased from 9.5 to 16.9 ng/mL at 3 hours (P<.0004) and returned to 10.5 by 24 hours. Prothrombin fragment 1.2 likewise transiently increased, from 0.34 to 0.51 nmol/L at 6 hours (P<.0002). Modified antithrombin III decreased over time (P<.002), and activated protein C increased from 2.3 to 4.5 ng/mL at 3 hours (P<.001). Although there were no clinical thrombotic events in the first 24 hours, 4 patients had evidence of ischemia by ST-segment monitoring at a median of 12 hours after heparin discontinuation. The degree of increase in fibrinopeptide A and prothrombin fragment 1.2 was not found to be associated with baseline diagnosis, duration of heparin therapy, baseline level of antithrombin III, or activated protein C.
Conclusions This study demonstrates a transient rebound increase in thrombin activity as well as in activated protein C upon abrupt discontinuation of intravenous heparin. Clinicians should be vigilant for associated thrombotic events. Further investigation of the significance, mechanism, and possible prevention of this rebound phenomenon is needed.
Key Words: angina • heparin • thrombosis
This article has been cited by other articles:
 |
|
 |
|
  P. H. Desai, D. Kurian, N. Thirumavalavan, S. P. Desai, P. Ziu, M. Grant, C. White, R. C. Landis, and R. S. Poston A Randomized Clinical Trial Investigating the Relationship Between Aprotinin and Hypercoagulabilityin Off-Pump Coronary Surgery Anesth. Analg., November 1, 2009; 109(5): 1387 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. Newsome, R. S. Weller, J. C. Gerancher, M. A. Kutcher, and R. L. Royster Coronary Artery Stents: II. Perioperative Considerations and Management Anesth. Analg., August 1, 2008; 107(2): 570 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Ho, E. D. Peterson, L. Wang, D. J. Magid, S. D. Fihn, G. C. Larsen, R. A. Jesse, and J. S. Rumsfeld Incidence of Death and Acute Myocardial Infarction Associated With Stopping Clopidogrel After Acute Coronary Syndrome JAMA, February 6, 2008; 299(5): 532 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Dent, Z. Lekic, and M. Vicenzi Unfractionated heparin and coronary artery stenting. Br. J. Anaesth., October 1, 2006; 97(4): 582 - 582. [Full Text] [PDF]
|
|
|
|
|
|
M. Di Nisio, N. R. Bijsterveld, J. C.M. Meijers, M. Levi, H. R. Buller, and R. J.G. Peters Effects of Clopidogrel on the Rebound Hypercoagulable State After Heparin Discontinuation in Patients With Acute Coronary Syndromes J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1582 - 1583. [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Gurbuz, W. G. Elliott, and A. A. Zia Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines Eur. J. Cardiothorac. Surg., January 1, 2005; 27(1): 138 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M Antman The re-emergence of anticoagulation in coronary disease Eur. Heart J. Suppl., April 1, 2004; 6(suppl_B): B2 - B8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Wallentin Oral direct thrombin inhibition for anticoagulation in coronary artery disease - focus on the ESTEEM trial Eur. Heart J. Suppl., April 1, 2004; 6(suppl_B): B9 - B14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Roe, C. L. Green, R. P. Giugliano, C. M. Gibson, K. Baran, M. Greenberg, S. T. Palmeri, S. Crater, K. Trollinger, K. Hannan, et al. Improved speed and stability of st-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute st-segment elevation myocardial infarction J. Am. Coll. Cardiol., February 18, 2004; 43(4): 549 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.W. Eikelboom, J.I. Weitz, A. Budaj, F. Zhao, I. Copland, P. Maciejewski, M. Johnston, and S. Yusuf Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes Eur. Heart J., November 2, 2002; 23(22): 1771 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kottke-Marchant, M.C. Bahit, C.B. Granger, P. Zoldhelyi, D. Ardissino, L. Brooks, J.H. Griffin, R.F. Potthoff, F. Van de Werf, R.M. Califf, et al. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes Eur. Heart J., August 1, 2002; 23(15): 1202 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Bijsterveld, A. H. Moons, J. C. M. Meijers, J. G. P. Tijssen, H. R. Buller, M. Levi, and R. J. G. Peters Rebound thrombin generation after heparin therapy in unstable angina: A randomized comparison between unfractionated and low-molecular-weight heparin J. Am. Coll. Cardiol., March 6, 2002; 39(5): 811 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Lauer, P. L. Houghtaling, J. G. Peterson, C. B. Granger, D. L. Bhatt, S. K. Sapp, M. L. Simoons, R. A. Harrington, E. J. Topol, and A. M. Lincoff Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary Syndromes: Observations From the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Circulation, December 4, 2001; 104(23): 2772 - 2777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. G. Turpie and E. M. Antman Low-Molecular-Weight Heparins in the Treatment of Acute Coronary Syndromes Arch Intern Med, June 25, 2001; 161(12): 1484 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Oldgren, R. Linder, L. Grip, A. Siegbahn, and L. Wallentin Coagulation Activity and Clinical Outcome in Unstable Coronary Artery Disease Arterioscler Thromb Vasc Biol, June 1, 2001; 21(6): 1059 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Abendschein, P. K. Baum, P. Verhallen, P. R. Eisenberg, M. E. Sullivan, and D. R. Light A Novel Synthetic Inhibitor of Factor Xa Decreases Early Reocclusion and Improves 24-h Patency after Coronary Fibrinolysis in Dogs J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 567 - 572. [Abstract] [Full Text]
|
|
|
|
|
|
M. C. Bahit, E. J. Topol, R. M. Califf, P. W. Armstrong, D. A. Criger, V. Hasselblad, A. Betriu, J. Hirsh, D. Ardissino, and C. B. Granger Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1001 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Figueras, Y. Monasterio, R. M. Lidon, E. Nieto, and J. Soler-Soler Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2036 - 2043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062. [Full Text] [PDF]
|
|
|
|
|
|
M.D Flather, J.I Weitz, S Yusuf, J Pogue, B Sussex, J Campeau, J Gill, R Schuld, C.D Joyner, A.L Morris, et al. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial Eur. Heart J., September 1, 2000; 21(17): 1473 - 1481. [Abstract] [PDF]
|
|
|
|
|
|
R. C. Becker, F. A. Spencer, Y. Li, S. P. Ball, Y. Ma, T. Hurley, and J. Hebert Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: Potential mechanisms for heightened prothrombotic potential J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1020 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Matthai Jr., P. B. Kurnik, W. C. Groh, W. J. Untereker, and J. E. Siegel Antithrombin activity during the period of percutaneous coronary revascularization: Relation to heparin use, thrombotic complications and restenosis J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1248 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Frostfeldt, G. Ahlberg, G. Gustafsson, G. Helmius, B. Lindahl, A. Nygren, A. Siegbahn, E. Swahn, P. Venge, and L. Wallentin Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction--a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II) J. Am. Coll. Cardiol., March 1, 1999; 33(3): 627 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Weitz, E. Young, M. Johnston, A. R. Stafford, J. C. Fredenburgh, and J. Hirsh Vasoflux, a New Anticoagulant With a Novel Mechanism of Action Circulation, February 9, 1999; 99(5): 682 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Liron, P. Theroux, H. D. White, The PRISM Study Investigators, J. H. Chesebro, and J. J. Badimon Tirofiban in Unstable Coronary Disease N. Engl. J. Med., October 15, 1998; 339(16): 1163 - 1165. [Full Text]
|
|
|
|
|
|
The Platelet Receptor Inhibition in Ischemic Syndr A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina N. Engl. J. Med., May 21, 1998; 338(21): 1498 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Global Use of Strategies to Open Occluded Coro A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes N. Engl. J. Med., September 12, 1996; 335(11): 775 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. D'Angelo, B. G. Oliver, M. G. Davis, T. S. McCluskey, and G. W. Dorn II Novel Role for Sp1 in Phorbol Ester Enhancement of Human Platelet Thromboxane Receptor Gene Expression J. Biol. Chem., August 16, 1996; 271(33): 19696 - 19704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Granger, J. Hirsh, R. M. Califf, J. Col, H. D. White, A. Betriu, L. H. Woodlief, K. L. Lee, E. G. Bovill, R. J. Simes, et al. Activated Partial Thromboplastin Time and Outcome After Thrombolytic Therapy for Acute Myocardial Infarction : Results From the GUSTO-I Trial Circulation, March 1, 1996; 93(5): 870 - 878. [Abstract] [Full Text]
|
|